RT @influenzer3: ●ACEI/ARBの使用はCOVID-19における予後良好因子 →これが三報目でかつ決定版かと。 もうこれについては決着がついたと言えるように思います。 https://t.co/DkbC4lpprr
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
RT @SantasEnrique: Datos que de nuevo refuerzan NO suspender IECA/ARA-2 en pacientes con HTA 🏥 por #COVID19. Menor riesgo de mortalidad e…
RT @EmilioOrtegaMdV: IECA/ARA2: menor mortalidad en pacientes ingresados por COVID19. Mejor calidad de estudio diferentes noticias. Circula…
cc: @scottlastname
RT @influenzer3: ●ACEI/ARBの使用はCOVID-19における予後良好因子 →これが三報目でかつ決定版かと。 もうこれについては決着がついたと言えるように思います。 https://t.co/DkbC4lpprr
とりあえず、ミカルディスを服用していても大丈夫ということか。
RT @influenzer3: ●ACEI/ARBの使用はCOVID-19における予後良好因子 →これが三報目でかつ決定版かと。 もうこれについては決着がついたと言えるように思います。 https://t.co/DkbC4lpprr
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
RT @influenzer3: ●ACEI/ARBの使用はCOVID-19における予後良好因子 →これが三報目でかつ決定版かと。 もうこれについては決着がついたと言えるように思います。 https://t.co/DkbC4lpprr
RT @influenzer3: ●ACEI/ARBの使用はCOVID-19における予後良好因子 →これが三報目でかつ決定版かと。 もうこれについては決着がついたと言えるように思います。 https://t.co/DkbC4lpprr
RT @trishgreenhalgh: ACE inhibitors and Angiotensin Receptor blockers do not appear to be associated with increased mortality in covid-19 p…
RT @influenzer3: ●ACEI/ARBの使用はCOVID-19における予後良好因子 →これが三報目でかつ決定版かと。 もうこれについては決着がついたと言えるように思います。 https://t.co/DkbC4lpprr
RT @influenzer3: ●ACEI/ARBの使用はCOVID-19における予後良好因子 →これが三報目でかつ決定版かと。 もうこれについては決着がついたと言えるように思います。 https://t.co/DkbC4lpprr
RT @trishgreenhalgh: ACE inhibitors and Angiotensin Receptor blockers do not appear to be associated with increased mortality in covid-19 p…
RT @influenzer3: ●ACEI/ARBの使用はCOVID-19における予後良好因子 →これが三報目でかつ決定版かと。 もうこれについては決着がついたと言えるように思います。 https://t.co/DkbC4lpprr
RT @influenzer3: ●ACEI/ARBの使用はCOVID-19における予後良好因子 →これが三報目でかつ決定版かと。 もうこれについては決着がついたと言えるように思います。 https://t.co/DkbC4lpprr
RT @influenzer3: ●ACEI/ARBの使用はCOVID-19における予後良好因子 →これが三報目でかつ決定版かと。 もうこれについては決着がついたと言えるように思います。 https://t.co/DkbC4lpprr
RT @EmilioOrtegaMdV: IECA/ARA2: menor mortalidad en pacientes ingresados por COVID19. Mejor calidad de estudio diferentes noticias. Circula…
●ACEI/ARBの使用はCOVID-19における予後良好因子 →これが三報目でかつ決定版かと。 もうこれについては決着がついたと言えるように思います。 https://t.co/DkbC4lpprr
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
RT @venkmurthy: I coauthored editorial on the paper w/ @RaviShah_MD Paper isn't perfect. *Lots* of limitations. Many of which are pointed…
RT @trishgreenhalgh: ACE inhibitors and Angiotensin Receptor blockers do not appear to be associated with increased mortality in covid-19 p…
RT @PotardDechaine: “Il est vachement bien ce petit, c’est moi qui l’ai repéré, c’est moi qui l’ai formé”. Raoult (Volfoni). 👇👇👇
RT @srrezaie: IMPORTANT STUDY --> Zhang P et al. Association of Inpatient Use of ACEI/ARBs with 28d Mortality Among Pts with HTN Hospitaliz…
RT @venkmurthy: I coauthored editorial on the paper w/ @RaviShah_MD Paper isn't perfect. *Lots* of limitations. Many of which are pointed…
RT @venkmurthy: I coauthored editorial on the paper w/ @RaviShah_MD Paper isn't perfect. *Lots* of limitations. Many of which are pointed…
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
This study is way beyond my expertise. But the most conservative conclusion seems to be that ACEi/ARB meds to manage hypertension don't seem to increase risk of mortality during Covid-19 infection. Ofc more rigorous studies needed, but this is slightly rea
ECA e BRA e mortalidade por covid-19
RT @catcardiocamfic: En pacients hospitalitzats amb #COVID19 amb HTA, l’us d’IECA/ARA2 es va associar a menor mortalitat que en els que no…
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
Merci c’est plus clair (ou pas vraiment en fait en attendant des publis plus « robustes »
RT @trishgreenhalgh: ACE inhibitors and Angiotensin Receptor blockers do not appear to be associated with increased mortality in covid-19 p…
RT @trishgreenhalgh: ACE inhibitors and Angiotensin Receptor blockers do not appear to be associated with increased mortality in covid-19 p…
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
RT @catcardiocamfic: En pacients hospitalitzats amb #COVID19 amb HTA, l’us d’IECA/ARA2 es va associar a menor mortalitat que en els que no…
Diminution de 60% de la mortalité par #COVID19 chez les patients ayant une #hypertension artérielle par l'utilisation d'un antihypertenseur sartan/IEC. Une étude chinoise publiée aujourd'hui par l'AHA et qui donne beaucoup d'espoir. https://t.co/wXXQUq21L
RT @hswapnil: (yet another!) update on the #NephJC #COVIDACE2 page Link https://t.co/vwnT0YMkQw Added data on a @CircRes paper https://t.…
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
RT @catcardiocamfic: En pacients hospitalitzats amb #COVID19 amb HTA, l’us d’IECA/ARA2 es va associar a menor mortalitat que en els que no…
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
Nueva Evidencia apoya la recomendación de NO SUSPENDER los medicamentos antihipertensivos en COVID-19. https://t.co/sGeTrdxdVS https://t.co/4f1xZ8kNsS
RT @SantasEnrique: Datos que de nuevo refuerzan NO suspender IECA/ARA-2 en pacientes con HTA 🏥 por #COVID19. Menor riesgo de mortalidad e…
In another multi-centre UK study: ACE-inhibitors in patients with pre-existing hypertension assoc with less #COVID19 severity (decreased requirement for ICU care) & lower mortality -14% on ACEi died or required ICU -29% with no ACEi died or required IC
RT @catcardiocamfic: En pacients hospitalitzats amb #COVID19 amb HTA, l’us d’IECA/ARA2 es va associar a menor mortalitat que en els que no…
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
cc @awhspeed although lots of caveats https://t.co/hJYZQBCdAk
We went from "risk factor" to "protective factor" for the ACE1/ARBs, in less than 2 weeks. Conclusion: Hopeful, but needs more data, replication in other cohorts.
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
RT @catcardiocamfic: En pacients hospitalitzats amb #COVID19 amb HTA, l’us d’IECA/ARA2 es va associar a menor mortalitat que en els que no…
RT @catcardiocamfic: En pacients hospitalitzats amb #COVID19 amb HTA, l’us d’IECA/ARA2 es va associar a menor mortalitat que en els que no…
RT @trishgreenhalgh: ACE inhibitors and Angiotensin Receptor blockers do not appear to be associated with increased mortality in covid-19 p…
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
Observational study—striking difference in mortality rates among hospitalized #COVID19 patients with pre-existing hypertension -3.7% on an ACEi/ARB died -9.8% with no ACEi/ARB died ▶️https://t.co/In2XP1Puyq Need to await RCTs—5 ACEi/ARB clinical trials un
RT @cpvio: Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Amo…
RT @catcardiocamfic: En pacients hospitalitzats amb #COVID19 amb HTA, l’us d’IECA/ARA2 es va associar a menor mortalitat que en els que no…
RT @CircRes: Are ACE/ARB inhibitors safe for #COVID19 patients? https://t.co/FGsCthPS24 A new observational study suggests that use of #A…
En pacients hospitalitzats amb #COVID19 amb HTA, l’us d’IECA/ARA2 es va associar a menor mortalitat que en els que no en prenien @CircAHA Sembla més clar encara que no s’han de retirar aquests farmacs! @catcardio @CAMFiC https://t.co/dqZQ2yKLNA
Article dans publication research sur les IEC/ARA2 dans le covid. Cet article là a passé le peer-reviewing dans une grosse revue (IF à 15) donc à prendre en considération. @aragon_jb @Damkyan_Omega https://t.co/gLwOKe1MLE
RT @ABsteward: Surprising! @CircRes @CircAHA Among hospitalized COVID-19 patients with hypertension, inpatient use of ACEI/ARB was associat…
RT @AnilMadhavan: ACEI / ARB not associated with increased mortality in Covid. Could even be protective according to this paper. https://t…
RT @GowSte: @orthoandtrauma @zobobarroni
Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19 | Circulation Research https://t.co/WnkOa0njBu
RT @trishgreenhalgh: ACE inhibitors and Angiotensin Receptor blockers do not appear to be associated with increased mortality in covid-19 p…
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
RT @trishgreenhalgh: ACE inhibitors and Angiotensin Receptor blockers do not appear to be associated with increased mortality in covid-19 p…
RT @srrezaie: IMPORTANT STUDY --> Zhang P et al. Association of Inpatient Use of ACEI/ARBs with 28d Mortality Among Pts with HTN Hospitaliz…
RT @DavidJuurlink: Wow. Among patients hospitalized with COVID, strikingly *lower* mortality for those on an ACEi/ARB On an ACEi/ARB: 3.7%…
RT @trishgreenhalgh: ACE inhibitors and Angiotensin Receptor blockers do not appear to be associated with increased mortality in covid-19 p…
RT @FZores: papier de Circulation Research sur IEC/ARA2 et COVID https://t.co/36hyftxDR2
RT @trishgreenhalgh: ACE inhibitors and Angiotensin Receptor blockers do not appear to be associated with increased mortality in covid-19 p…
RT @edgarvlermamd: Among hospitalized #COVID19 patients w/ hypertension 📌 Inpatient use of ACEI/ARB ~ asso. w/ ⬇️ risk of all-cause mortali…
Utile et intelligent
Large (n=1128) Chinese retrospective trial suggesting a LOWER mortality for #COVIDー19 pts receiving ACE-I/ARBs for hypertension Hard to draw conclusions on the subject, but I’d definitely not withdraw an ongoing tx with ACE-I/ARB @OncoAlert https://t.co/
“Il est vachement bien ce petit, c’est moi qui l’ai repéré, c’est moi qui l’ai formé”. Raoult (Volfoni). 👇👇👇
RT @DrRajivsankar: https://t.co/1GPwvDeGdD Retrospective data with associated limitations but lower mortality in hospitalised COVID patient…
RT @trishgreenhalgh: ACE inhibitors and Angiotensin Receptor blockers do not appear to be associated with increased mortality in covid-19 p…
RT @srrezaie: IMPORTANT STUDY --> Zhang P et al. Association of Inpatient Use of ACEI/ARBs with 28d Mortality Among Pts with HTN Hospitaliz…
Stopping ACE inhibitors in patients admitted with COVID19 never made sense to me as it can worsen RAAS inflammation but I reported this because of concern of high ACE2 expression. Now the data is very clear- Do not stop ACEI unless there is kidney injury